Keywords: new, data, repligen, rg2133, usa-based, released, positive

New data for Repligen's RG2133

Article | 21 June 2004

Print This

USA-based Repligen has released positive findings from a Phase I, open-label trial of its RG2133, a prodrug of uridine. The ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in